ep guid oper fine-
ep consensu cah adj ep
exceed estim weaker profit off-set factor
line ad introduc ep guidanc
bracket estim consensu incorpor
slower profit growth higher interest expens off-set lower tax
rate share base maintain ep
tp move temper profit growth trajectori
revenu ahead profit disappoint revenu
stronger core growth vs estimate
medic also ahead plan segment oper profit
growth pharma well view tougher gener
price environ post notabl weaker medic profit growth
also plan reflect on-going cordi challeng
ebit margin fell bp bp plan gener million
cash facilit million buyback million dividend
share ebb expect remain clearli low share
trend lower short term latest oper miss
disappoint initi guidanc point weaker expect
profit growth across pharma medic segment expos
prolong challeng diversif strategi call hsd-
ldd pharma profit growth face oner drug price environ
optum contract headwind msd-hsd medic profit growth
cordi woe divestitur focu call abil address
medic execut recent acquisitions/divestitur evolv rebat
paradigm drug price remain posit dispos
stock patienc challeng latest shortfal risk drug
price acquisit miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
million
compani data credit suiss estim bloomberg profession servic streetaccount
compani mention price
